Correction: A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus
Pulm Ther
.
2025 Jun;11(2):305.
doi: 10.1007/s41030-025-00298-y.
Authors
Mickie H Cheng
1
,
Alex J Mann
2
,
Brian M Maas
3
,
Tian Zhao
3
,
Melissa Bevan
2
,
Andrea K Schaeffer
3
,
Laura E Liao
3
,
Andrew P Catchpole
2
,
David W Hilbert
3
,
S Aubrey Stoch
3
,
Carisa S De Anda
3
Affiliations
1
Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ, 07065, USA. mickie.cheng@merck.com.
2
hVIVO Services Ltd., London, UK.
3
Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ, 07065, USA.
PMID:
40346422
PMCID:
PMC12102405
DOI:
10.1007/s41030-025-00298-y
No abstract available
Publication types
Published Erratum